Breakpoint Therapeutics Announces Poster Presentation at the 36th EORTC-NCI-AACR Symposium
- Managing Director Jon Hollick will present preclinical data from Breakpoint’s polymerase theta (Pol θ / POLQ) inhibitor programme at ENA 2024
Hamburg, Germany, 17 October 2024
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024).
DNA polymerase theta is a DNA repair enzyme that is largely absent in normal cells but displays aberrant expression in multiple cancer types which often correlates with poor prognosis. Inhibition of Pol θ is a validated therapeutic modality in certain tumour-specific contexts.
Details of the presentation are as follows:
Abstract Title: Discovery and characterisation of DNA polymerase theta inhibitors for the treatment of cancer
Date: Friday, 25 October, 2024
Time: 9:00 a.m. – 3:00 p.m. CEST
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Abstract Number: 339
Poster Board Number: PB327
– end –
About ENA 2024
ENA 2024 gathers over 1500 clinical researchers, scientists and industry representatives from across the globe to discuss data which will drive treatment and care in the coming years. It stands as the drug development and translational research meeting, giving the spotlight to the latest preclinical and clinical research on novel targets and therapies.
About Breakpoint Therapeutics
Breakpoint Therapeutics is developing targeted cancer therapies that modulate DNA damage response (DDR) pathways. Through precise interference with DNA repair, our drug candidates are designed to kill cancer cells without harming healthy cells. We leverage new insights and the concept of synthetic lethality to increase the therapeutic window and achieve better outcomes for patients with therapy-resistant and hard-to-treat cancers.
For more about Breakpoint Therapeutics: www.breakpointtx.com
